Excel Diagnostics and Nuclear Oncology Center

Houston, Texas 77042

3 studies enrolling now · 14 studies all time

What they study most

Biochemical Recurrence of Malignant Neoplasm of Prostate, Bone Metastases in Subjects With Advanced Cancer, Bone Pain, Carcinoid Tumor of the Small Bowel, Coronary Artery Disease, Metastatic Bone Tumor, Metastatic Castration Resistant Prostate Cancer, Neuroendocrine Breast Tumor, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Neoplasm of Ovary, Neuroendocrine Skin Carcinoma, Neuroendocrine Tumor

Studies at this site

• A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer — Recruiting now
• Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer — Recruiting now
• Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain — Recruiting now
• Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients — Running, not enrolling
• Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). — Running, not enrolling
• Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer — Completed
• Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer — Completed
• Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET — Stopped early
• 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms — Completed
• Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. — Withdrawn before enrolling
• Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE — Completed
• A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours — Completed
• Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy — Stopped early
• A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD. — Completed